A reengineered hospital discharge program to decrease rehospitalization: a randomized trial
Brian W Jack, Veerappa K Chetty, David Anthony, Jeffrey L Greenwald, Gail M Sanchez, Anna E Johnson, Shaula R Forsythe, Julie K O'Donnell, Michael K Paasche-Orlow, Christopher Manasseh, Stephen Martin, Larry Culpepper, Brian W Jack, Veerappa K Chetty, David Anthony, Jeffrey L Greenwald, Gail M Sanchez, Anna E Johnson, Shaula R Forsythe, Julie K O'Donnell, Michael K Paasche-Orlow, Christopher Manasseh, Stephen Martin, Larry Culpepper
Abstract
Background: Emergency department visits and rehospitalization are common after hospital discharge.
Objective: To test the effects of an intervention designed to minimize hospital utilization after discharge.
Design: Randomized trial using block randomization of 6 and 8. Randomly arranged index cards were placed in opaque envelopes labeled consecutively with study numbers, and participants were assigned a study group by revealing the index card.
Setting: General medical service at an urban, academic, safety-net hospital.
Patients: 749 English-speaking hospitalized adults (mean age, 49.9 years).
Intervention: A nurse discharge advocate worked with patients during their hospital stay to arrange follow-up appointments, confirm medication reconciliation, and conduct patient education with an individualized instruction booklet that was sent to their primary care provider. A clinical pharmacist called patients 2 to 4 days after discharge to reinforce the discharge plan and review medications. Participants and providers were not blinded to treatment assignment.
Measurements: Primary outcomes were emergency department visits and hospitalizations within 30 days of discharge. Secondary outcomes were self-reported preparedness for discharge and frequency of primary care providers' follow-up within 30 days of discharge. Research staff doing follow-up were blinded to study group assignment.
Results: Participants in the intervention group (n = 370) had a lower rate of hospital utilization than those receiving usual care (n = 368) (0.314 vs. 0.451 visit per person per month; incidence rate ratio, 0.695 [95% CI, 0.515 to 0.937]; P = 0.009). The intervention was most effective among participants with hospital utilization in the 6 months before index admission (P = 0.014). Adverse events were not assessed; these data were collected but are still being analyzed.
Limitation: This was a single-center study in which not all potentially eligible patients could be enrolled, and outcome assessment sometimes relied on participant report.
Conclusion: A package of discharge services reduced hospital utilization within 30 days of discharge.
Funding: Agency for Healthcare Research and Quality and National Heart, Lung, and Blood Institute, National Institutes of Health.
Trial registration: ClinicalTrials.gov NCT00252057.
Figures


Source: PubMed
Aankomende klinische onderzoeken
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied...Nog niet aan het wervenMotor vaardigheden | Gezond | Uitvoerende functie
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCNog niet aan het wervenAnale plaveiselcelcarcinoom
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaNog niet aan het wervenReumatoïde artritis | Degeneratieve gewrichtsaandoening van de knieItalië
-
University of Wisconsin, MadisonAlkermes, Inc.Nog niet aan het werven
-
Virginia Commonwealth UniversityNog niet aan het wervenCerebraal oedeem | StralingsnecroseVerenigde Staten
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount...Nog niet aan het wervenKetamine | fMRI | Depressie - Ernstige depressieve stoornis | rTMS | Therapieresistente depressie (TRD)Verenigde Staten
-
Weill Medical College of Cornell UniversityBD2 LLCNog niet aan het wervenfMRI | Bipolaire stoornis (BD) | rTMS | Bipolaire 1 depressieVerenigde Staten
-
Xentria, Inc.Nog niet aan het werven
-
Yale UniversityNational Institute of Mental Health (NIMH)Nog niet aan het werven
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeWervingFeochromocytoom | Feochromocytoom/paraganglioom | Feochromocytoom, metastatisch | Feochromocytoom Kwaadaardig | Pheochromocytoma en paraganglioom (PPGL)Verenigd Koninkrijk
-
Carl Zeiss Meditec-Dublin CoCeWervingEpiretinaal membraan | Ziekte van het netvlies | Droge leeftijd gerelateerde maculaire degeneratie | Vitreoretinale afwijking | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal Pigment Epithelium (RPE) AtrophyVerenigde Staten
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityWervingCLDN18.2 positieve solide tumorenChina